Skip to main content

Inhibikase Therapeutics, Inc. (IKT)

NASDAQ: IKT · IEX Real-Time Price · USD
2.02 -0.08 (-3.81%)
Sep 24, 2021 1:32 PM EDT - Market open
Market Cap54.97M
Revenue (ttm)2.98M
Net Income (ttm)n/a
Shares Out12.24M
EPS (ttm)-0.74
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume193,541
Open2.06
Previous Close2.10
Day's Range2.01 - 2.10
52-Week Range1.74 - 11.80
Betan/a
Analystsn/a
Price Target13.50 (+568.3%)
Est. Earnings DateNov 11, 2021

About IKT

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical devel...

IndustryBiotechnology
IPO DateDec 23, 2020
Employees3
Stock ExchangeNASDAQ
Ticker SymbolIKT
Full Company Profile

Financial Performance

In 2020, IKT's revenue was $698,468, a decrease of -37.79% compared to the previous year's $1.12 million. Losses were -$2.85 million, -50.24% less than in 2019.

Financial Statements

News

Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatme...

ATLANTA, Sept. 23, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of P...

1 day ago - PRNewsWire

Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference

ATLANTA, Sept. 7, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disea...

2 weeks ago - PRNewsWire

Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity

ATLANTA, Aug. 16, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disea...

1 month ago - PRNewsWire

Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients

ATLANTA, July 26, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Pa...

1 month ago - PRNewsWire

Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock

ATLANTA, June 18, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disea...

3 months ago - PRNewsWire

Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today

Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT) are among the biggest bio...

Other symbols:APRE
3 months ago - Benzinga

Inhibikase Therapeutics Stock Drops After Follow-On Equity Offering Of $45M Issued At 26% Discount

Inhibikase Therapeutics Inc (NASDAQ: IKT) has priced an underwritten public offering of 15 million shares at $3/share for gross proceeds of approximately $45 million. The offer price represents a 26% di...

3 months ago - Benzinga

Inhibikase Therapeutics Prices Follow-On Public Offering of Common Stock

ATLANTA, June 15, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disea...

3 months ago - PRNewsWire

Inhibikase Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference & Others

ATLANTA, May 25, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's diseas...

3 months ago - PRNewsWire

Inhibikase Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity

ATLANTA, May 17, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's diseas...

4 months ago - PRNewsWire

Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum

ATLANTA, April 21, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's dise...

5 months ago - PRNewsWire

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Acti...

ATLANTA, April 1, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease (PD) and r...

5 months ago - PRNewsWire

Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference

ATLANTA, Feb. 22, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disor...

7 months ago - PRNewsWire

Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson's D...

ATLANTA--(BUSINESS WIRE)--Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and relate...

7 months ago - Business Wire

Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as I...

ATLANTA, Jan. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disord...

8 months ago - PRNewsWire

Inhibikase Therapeutics Announces Closing of Initial Public Offering

ATLANTA, Dec. 28, 2020 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase"), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related dis...

8 months ago - PRNewsWire

Inhibikase Therapeutics, Inc. Announces Pricing of its Initial Public Offering

/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related...

9 months ago - PRNewswire

US IPO Weekly Recap: Postponements abound as DoorDash joins the IPO pipeline

Eight SPACs went public this past week but no IPOs, as all three scheduled deals postponed or withdrew. New filing activity picked up, led by long-awaited delivery service unicorn DoorDash (DASH), and s...

10 months ago - NASDAQ

Neurodegenerative disease biotech Inhibikase Therapeutics lowers proposed deal size by 40% ahead of $15 million IPO

Inhibikase Therapeutics, a clinical stage biotech developing kinase inhibitors for Parkinson's and related disorders, lowered the proposed deal size for its upcoming IPO on Tuesday. The Atlanta, GA-base...

10 months ago - NASDAQ

Inhibikase Files Registration Statement for Proposed Initial Public Offering | BioSpace

Inhibikase Files Registration Statement for Proposed Initial Public Offering - read this article along with other careers information, tips and advice on BioSpace

1 year ago - BioSpace